Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06789289 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

StatusActive, Not Recruiting
PhasePhase 2
Started2025-03-17
View on ClinicalTrials.gov ↗

Amendment history

2026-04-01
Not Yet Recruiting→Active, Not Recruiting Study Status, Study Design, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Active, Not Recruiting
Primary completion date2027-12→2027-03-17
Start dateestimated 2025-04→confirmed 2025-03-17
Eligibility criteria+1 characters
[...] assistive oxygen, the subject's oxygen saturation should be ≥< 89%; Undergone lung volume reduction surgery or procedures w [...]
Study sitescontacts updated at 40 of 40 sites
2025-01-17
Original filing
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It is anticipated that 256 subjects will be enrolled.
Trial Details
NCT Number NCT06789289
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 256 participants
Start Date 2025-03-17
Primary Completion 2027-03-17 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-07